(Reuters Health)—Patients give the same doctors different ratings depending on where their visit took place, according to a small U.S. study. Although doctors might act differently in an emergency department compared with a calmer office setting, researchers say the results also suggest that ratings are not a completely reliable measure of the quality of care…
Search results for: liver
U.S. Hospital Group Warns of Blue Cross Dominance if Anthem Buys Cigna
(Reuters)—The American Hospital Association warned U.S. antitrust regulators that Anthem Inc.’s proposed acquisition of Cigna Corp. will hurt other health insurers’ ability to compete with Blue Cross Blue Shield plans, leading to higher premiums for consumers. Anthem, the country’s second-largest health insurer, runs Blue Cross Blue Shield plans in 14 states. The hospital group, in…
Parents Often Catch Hospital Errors Doctors Missed
(Reuters Health)—Parents often catch medical errors that their child’s doctor missed, according to a U.S. study that suggests families may be an untapped resource for improving hospital safety and preventing mistakes. Roughly one in 10 parents spotted mistakes that physicians did not, according to the study of safety incidents observed on two pediatrics units at…
Rheumatologist, Pain Physician Collaboration Vital for Better Pain Control
Chronic pain can be one of the biggest challenges that patients and their physicians face. Rheumatology patients are no stranger to pain, and when pain goes beyond the scope of what rheumatologists can treat, collaboration with a pain specialist is common. “I refer patients to pain management when there is no underlying inflammatory condition, usual…
The ACR’s Grassroots Advocacy Efforts Rely on Rheumatology Patients
Over the past several years, the ACR has ramped up its efforts in advocacy. Under the leadership of the Government Affairs Committee, many ACR staff, members and their patients, considerable progress has been made moving priority issues forward in 2015. A few highlights from 2015 include: The Patients’ Access to Treatment Act (PATA) was introduced…
APS: What Rheumatologists Should Know about Hughes Syndrome
The problem that dogs the work of all of those treating patients with antiphospholipid syndrome (APS) is the apparent lack of knowledge of the syndrome, both by the general public, as well as by swaths of the medical fraternity. Perhaps it was ever thus—a syndrome less than 40 years old could be described as new,…
2015 ACR/ARHP Annual Meeting: Treatments for Transthyretin-Related Amyloidosis Generate Interest from Researchers, Pharmaceuticals
SAN FRANCISCO—Treatment for transthyretin-related amyloidosis (ATTR) is generating more interest from academic researchers and the pharmaceutical industry, with encouraging early results using a multi-pronged therapeutic approach, a researcher said at a review course held before the 2015 ACR/ARHP Annual Meeting. Amyloidoses are a rare and potentially deadly family of diseases in which misfolded protein builds…
2015 ACR/ARHP Annual Meeting: Metabolic Pathways Linked with Inflammatory Diseases
SAN FRANCISCO—Metabolomics could one day be a treasure map of information about inflammation in rheumatic disease. There are many metabolic pathways to pursue for clues on how to reverse this damaging process. “All of these signaling pathways are interrelated and affect each other,” said Douglas J. Veale, MD, director of translational research at Dublin Academic…
2015 ACR/ARHP Annual Meeting: Research Provides Insights into Immune Regulation and Tolerance
SAN FRANCISCO—To help rheumatologists better understand the underlying mechanisms of autoimmune diseases, Mark Anderson, MD, PhD, professor of adult endocrinology, University of California, San Francisco, spoke during the 2015 ACR/ARHP Annual Meeting on ways in which immune regulation and tolerance work to ensure health in individuals who maintain tolerance to self-antigens and how these processes…
2015 ACR/ARHP Annual Meeting: Role of Tumor Necrosis Factor Cytokines in Autoimmune Diseases Examined
SAN FRANCISCO—To date, evidence on the efficacy of blocking the cytokine tumor necrosis factor (TNF) and its receptors in autoimmune diseases has resulted in the approval by the Food and Drug Administration (FDA) of five anti-TNF agents. Less well known, according to Richard Siegel, MD, PhD, chief, Immunoregulation Section, Autoimmunity Branch, and Clinical Director, NIAMS,…
- « Previous Page
- 1
- …
- 74
- 75
- 76
- 77
- 78
- …
- 121
- Next Page »